In part 6 of our series, we made the case that elevated patient experience and engagement in cell and gene therapy (CGT) is a core commercial lever. Engagement, however, is only as good as the operational backbone behind it. A patient who has decided to pursue treatment still has to get to an authorized treatment center (ATC), navigate weeks of pre-treatment logistics, and stay engaged through a manufacturing, infusion, and monitoring timeline that bears little resemblance to anything in conventional specialty pharma. That operational backbone is the subject of this article: patient support services purpose-built for CGT, often described as “white glove”, despite being an overused and imperfect term.
Standard Hub Services Were Built for a Different Problem
The traditional specialty pharmacy hub model was designed around chronic, pharmacy-benefit therapies, and optimized for high-volume throughput: benefits investigation, prior authorization support, copay assistance, adherence reminders, and refill coordination, delivered efficiently at scale. However, CGT inverts this equation since they are often medical-benefit products (and in some cases, dual-benefit products) serving relatively small patient populations, and each patient requires something much closer to individual case management than to high-throughput transaction processing. Each traditional hub function is still important, but the operating model behind them needs to evolve. Effective CGT support programs need to deliver case-management-level support across:
- Community-to-ATC referral logistics, including identifying the right center and helping to shepherd the patient across their journey
- ATC scheduling and procedure coordination across (when relevant) apheresis conditioning, infusion, and post-infusion monitoring
- Travel and lodging coordination for patients and caregivers, often across state lines
- Manufacturing slot management and end-to-end shipment tracking for autologous products
- Financial and payer navigation that addresses both the therapy and the substantial ancillary costs around it, including copay assistance programs that function as a safety net when coverage falls short or leaves patients with out-of-pocket exposure they cannot absorb
All the above usually needs to be managed across a multi-week timeline where a missed handoff at any node can delay or derail the entire treatment. Successfully addressing all this is not a stretch goal. In fact, it’s the minimum baseline for a therapy where the patient may be one of only a handful at an ATC in a given month, and where a single misstep can mean a missed manufacturing slot, a missed insurance window, or a patient who simply doesn’t come back.
Customize for the Disease, Not Just the Drug
A second mistake worth avoiding is treating CGT patient support as a generic capability that can be bolted onto any program. The disease state, the patient population, and the institutional workflows at treatment centers vary enormously, and effective support programs are designed around those specifics.
A pediatric gene therapy program needs caregiver-centered support, school and family logistics, and tight coordination with a handful of highly specialized centers. An adult oncology CAR-T program needs to operate at higher volumes, integrate with community oncology referral patterns, and accommodate patients whose disease may progress during the wait. A program in sickle cell disease must contend with historically under-served populations, geographic gaps in specialized care, and a level of mistrust of the healthcare system that no standard call-center script will address. Patient population-specific attributes and burden must shape the design of the service.
The same principle applies at the institutional level. ATCs vary widely in how they intake CGT patients, how they handle financial clearance, and how their internal workflows integrate (or don’t) with manufacturer-provided support. Support programs that align with how a specific ATC actually operates, rather than asking the ATC to align with the manufacturer, are dramatically more effective.
Manage the Wait
Perhaps the most under-appreciated dimension of CGT support is what happens between enrollment and infusion. Depending on the product, that window can stretch from a few weeks to a couple of months, during which the patient has effectively committed to the therapy but has nothing concrete to do. They are waiting on apheresis scheduling, manufacturing progress, shipment, and infusion slot availability, often while their disease continues to progress. This is the most anxious phase of the entire journey, and it is the phase where standard hub models go quiet.
Programs that “manage the wait” recognize this and design proactive touchpoints into the period itself. Welcome calls after enrollment, regular status updates as manufacturing progresses, clear communication when shipment is initiated, and confirmed infusion scheduling with logistical details locked in well in advance all serve the same purpose: they keep the patient and caregiver oriented, informed, and emotionally engaged through a stretch of time that would otherwise feel like a void. This provides needed service while directly reducing attrition during the window where patients are most likely to disengage. It also reinforces the continuity of language and expectations that we discussed in part 6.
Support The Continuing Journey
Support doesn’t end when the infusion does. Most CGT products carry FDA-mandated long-term follow-up requirements, which can run from five years for AAV-based gene therapies to as long as fifteen years for products using integrating vectors, layered on top of near-term monitoring for known risks like cytokine release syndrome or delayed engraftment in the days and weeks immediately post-infusion. In practice, this means a schedule of return visits for labs, imaging, and clinical assessment that can stretch for years, sometimes back at the ATC, sometimes at a satellite site with a local physician working from a shared-care protocol the ATC has trained them on.
The white glove model needs to extend into this phase rather than treat infusion as the finish line: confirming which visits happen where and with whom, onboarding local providers who may never have managed a CGT patient before, keeping patients enrolled in required registries, and proactively re-engaging patients and caregivers whose motivation to show up for routine visits fades once the urgency of treatment has passed. Programs that let this phase go quiet risk the patient, plus they risk creating gaps in the long-term safety and durability data that regulators, payers, and the therapy’s own commercial narrative all depend on (the same evidence agenda we covered in part 5).
Decide What You Own and What You Outsource
One question cuts across everything above: who actually delivers each of these functions? An increasingly common pattern is a hybrid model, where the manufacturer retains some activities in-house and contracts others to external vendors. The split is driven by several factors: compliance considerations that argue for arm’s-length handling of certain interactions, capability gaps that vendors are better positioned to fill, and, in the other direction, a preference to own the touchpoints that carry the most direct connectivity to the patient. There is no single correct division, but the choice should be explicit rather than inherited from whatever the contracted vendor happens to offer. Importantly, the handoffs between internal and external teams need the same rigor as the handoffs between the ATC and the manufacturing site.
The Bottom Line
Rather than simply being a premium add-on for CGT, this high level of patient support is the operational expression of the engagement strategy. It plays a key role in determining whether enrolled patients actually reach infusion. Manufacturers that go well beyond standard hub services, design for specific disease attributes and burden, and proactively manage the wait between enrollment and infusion are the ones whose programs deliver consistent throughput. Those that rely on conventional hub models tend to find that the gap between enrollment and treatment is exactly where the chain tends to break.
Next in the series: Success Factor 8 – Internal Training and Cross-Functional Coordination.
